The reduction in exacerbation rates following multidisciplinary intervention was most pronounced in patients with mild to moderate disease severity. A multidisciplinary program for bronchiectasis and ...
Rationale Recently a frequent exacerbator phenotype has been described in bronchiectasis, but the underlying biological mechanisms are unknown. Antimicrobial peptides (AMPs) are important in host ...
Dublin, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The "Bronchiectasis - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides top line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results